Citation only via OpenAlex

Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration

Napoleone Ferrara, ROBERT D. MASS, Claudio Campa, Robert Kim

Annual Review of Medicine · 2006 · ▲ 238 citations

Genomic instability Human Review

Abstract

Inhibiting angiogenesis is a promising strategy to treat cancer and several other disorders, including intraocular neovascular syndromes. The identification of vascular endothelial growth factor (VEGF)-A as a major regulator of normal and pathological angiogenesis has enabled significant progress toward effective treatments for such disorders. Several VEGF inhibitors have been recently approved by the U.S. Food and Drug Administration for the treatment of cancer and the neovascular form of age-related macular degeneration. This review summarizes the basic biology of VEGF-A and illustrates the clinical progress in targeting this molecule.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: OpenAlex
DOI: 10.1146/annurev.med.58.061705.145635
Canonical: link ↗
Fetched: 2026-10-19 MST

Cite this

APA

Ferrara, N., MASS, R.D., Campa, C., & Kim, R. (2006). Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration. <em>Annual Review of Medicine</em>. https://doi.org/10.1146/annurev.med.58.061705.145635

Vancouver

Ferrara N, MASS RD, Campa C, Kim R. Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration. Annual Review of Medicine. 2006. doi:10.1146/annurev.med.58.061705.145635.

BibTeX

@article{napoleone2006Target, title = {Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration}, author = {Napoleone Ferrara and ROBERT D. MASS and Claudio Campa and Robert Kim}, journal = {Annual Review of Medicine}, year = {2006}, doi = {10.1146/annurev.med.58.061705.145635}, }